Description
Ezutromid is a first orally available drug for the treatment of Duchenne muscular dystrophy (DMD), a lethal, X-linked muscle wasting disease caused due to lack of dystrophin-a cytoskeleton protein. Ezutromid has shown potential as disease modifying treatment for DMD patients irrespective of their gene mutation. Ezutromid acts on utrophin modulation and has potential to slow down or stop the progression of DMD.
Ezutromid is a first orally available drug for the treatment of Duchenne muscular dystrophy (DMD), a lethal, X-linked muscle wasting disease caused due to lack of dystrophin-a cytoskeleton protein. Ezutromid has shown potential as disease modifying treatment for DMD patients irrespective of their gene mutation. Ezutromid acts on utrophin modulation and has potential to slow down or stop the progression of DMD.
Alternate Name/Synonyms: 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole; BMN195
Appearance: Light brown solid
Formulation: N/A
CAS Number: 945531-77-1
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₉H₁₅NO₃S
Molecular Weight: 337.39
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO(>10 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A drug for the treatment of Duchenne muscular dystrophy (DMD),
MDL Number: N/A
PubChem CID: 25109292
SMILES: CCS(=O)(=O)C1=CC2=C(C=C1)OC(=N2)C3=CC4=CC=CC=C4C=C3
InChi: InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3
InChi Key: KSGCNXAZROJSNW-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |